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Abstract: 
If the field of regenerative medicine is to deliver therapies, rapid expansion and delivery 
over considerable distances to large numbers of patients is needed. This will demand 
efficient stabilization and shipment of cell products. However, cryopreservation science 
is poorly understood by life-scientists in general and in recent decades only limited 
progress has been made in the technology of preservation and storage of cells. Rapid 
translation of new developments to a broader range of cell types will be vital, as will 
assuring a deeper knowledge of the fundamental cell biology relating to successful 
preservation and recovery of cell cultures. This report presents expert consensus on 
these and other issues which need to be addressed for more efficient delivery of cell 
therapies. 
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Background 
The ability to reliably preserve cell preparations for therapy and ship them to healthcare 
centers nationally and internationally presents a key challenge for the delivery of cell 
therapies. However, the subject  of preservation and subsequent shipment, the so-called 
‘cold-chain,’ has received limited support from funding agencies and key scientific and 
technical challenges remain which present barriers to effective and economic roll-out of 
new potential cell therapy products. Initiation of an expert Steering Group was led jointly by 
the Cell and Gene Therapy Catapult and the National Institute for Biological Standards 
and Control (NIBSC, a center of the Medicines and Healthcare products Regulatory 
Agency) to develop a strategic framework on key issues in the development  of  our  
understanding of the technology for sustaining the stability of cell therapy products for 
delivery and   storage.   Representatives   of  NIBSC  and Cell and Gene Therapy Catapult 
with other experts formed  a  Steering  Group (see Supplementary Appendix 1) to draw 
together, following a focused workshop, a consensus on key challenges and 
recommendations to make progress in assuring successful and stable preservation and 
shipment of cells for therapy. The workshop took place at the NIBSC in May 2015. The 
remit of the workshop was to garner relevant scientific expertise from industry and 
academia to address current state of the art, translational gaps in science and technology 
and areas that require further research. Furthermore, it sought to identify  potential ways 
forward to improve coordination and provision of advice to resolve central issues for 
companies and healthcare services delivering advanced therapy products. A meeting report 
from the workshop with recommendations agreed by delegates has since been reviewed by 
the Steering Group and meeting delegates and is presented here providing an expert 
consensus for use by research funders, regulatory bodies, healthcare professionals and 
researchers. 
 
 
Session 1: Categories of cell systems 
The challenges of preservation are influenced by the nature of individual cells such as their 
size, membrane permeability, morphology,  ultrastructural  complexity and composition of 
subcellular organelles, as well as the cell density and composition of the preservation 
medium (see reviews in [1–3]). A fundamental underlying factor to  cryopreservation in any 
format  is water stress (due to osmotic effects and ice formation), which the group believed 
to be still poorly understood, and requires further basic research 
 
These defining characteristics are complicated by the presence of multiple cell types or 
their combination with noncellular components, such as extracellular matrix or artificial 
scaffolds in certain therapies. While it was clear that a one-size-fits-all approach to 
preservation of cellular function across such a diverse spectrum of cell therapy products 
was impracticable, a rationalized approach is needed as the empirically derived processes 
would not be the same in different systems. While no cell system is completely homog- 
enous, it was concluded that it would be helpful to develop a set of simple cell-based model 
systems to understand the challenges of preserving key types of cell therapies (see Box 1 
 for Recommendation 1). Such cell-based models systems could enable the development of 
new approaches for  preservation and storage at ultra-low or  otherwise controlled  
conditions. It was envisaged that these systems should include a uniform cell suspension 
type (such as blood-derived T cells), undifferentiated human pluripotent stem cells, cell 
aggregates (e.g., hepatocytes, neurons) and a combination product such as mixture of 
fibroblasts and keratinocytes. An overall structure for these model systems should also 
take into account the processing involved, scale of processing and in particular the time 
between preparation and delivery to the patient, as illustrated in Figure 1. It  will  be  impor- 
tant to understand the different potential responses  of cells in vivo versus in vitro. 
Furthermore, it would be important in these studies, to minimize the influence of operator 
variability and the group concluded that automated processing was now sufficiently well 
developed to provide processing solutions that could eliminate this source  of variability. 
 
Session 2: Fundamentals of preservation & recovery 
Successful preservation is  dependent  on  a  number of  pre-preservation  strategies  in  
addition  to  those already mentioned above. The culture methodology may influence cell 
morphology and can be adjusted (typically into the logarithmic phase of growth where cells 
often display a high nuclear/cytoplasmic volume ratio). Cellular permeability may change 
with temperature which may need to be taken into account for the development of cooling 
profiles. Water content is clearly a critical issue in cryopreservation of cell preparations but 
it was recognized that all ultra-low temperature preservation methods ultimately invoked 
vitrification even if only as a final event during cooling. This has implications for method 
development and  storage conditions [4]. Vitrification by rapid freezing has proven useful in 
several systems, but suffers from the difficulty in maintaining the integrity of cell–matrix 
structures, amenability of thawing procedures for routine clinical use [5] and scalability. The  
group  noted that the benefits of vitrification methods had yet to    be realized but may be 
enabled by the development of automated freezing and thawing systems  [6–8]. 
 
The group considered that one of the major issues, which had held back the development 
of new and more effective preservation methods, was the com- mon practice in published 
literature to report measurements of viability immediately post thaw. In the absence of 
contextualization of the preparation and condition of cells prior to preservation or indeed a 
suitable timeframe and a short time after recovery (when consequences of the preservation 
process on viability and cellular function were clearer), this was a confounding issue. 
 
It was recognized that some cellular systems that appear to have similar characteristics 
may respond very differently to a preservation methods. This observation may be due to 
differences in their prior expo- sure to environmental conditions, direct or indirect activity 
of other cells to which they have been exposed and other bioprocessing factors. 
Approaches to preservation, shipment and recovery would therefore need to take such 
factors into account and provide coherent records of results (see Box 2 for 
Recommendation 2). Delivery of cell therapy products to large numbers of patients is 
unlikely to be achieved using a continuous culture manufacturing process and will require 
the ability to  produce  and  preserve  large  batches or necessitate multiple site 
manufacturing. Closely controlled workflows and culture conditions should increase 
consistency in the cellular preparations and the ability to recover consistently viable and 
functional cells. However, it was concluded that the cur- rent reality was that it may be 
necessary to accept substantial losses of cells and accommodate reason- able recovery 
 of adequate cell populations for clinical use. However, as for any preservation process, it 
would be necessary to demonstrate consistency between the pre- and post-preservation 
cells to give confidence that potency/efficacy of the cell product for its intended purpose 
was sustained. The preservation and recovery of cell preparations clearly represents a 
dynamic process of changing cell condition and snap-shot quality control of cell recovery 
may be significantly misleading, particularly for cell analysis immediately post thaw. It was, 
therefore, concluded that at least when developing new or modified preservation methods, 
recovery of cell preparations needed to be monitored over a period of time post thawing, to 
create a profile of cell recovery  and  replication until  full functionality  was attained. 
 
Session 3: Characterization of cellular preparations 
Traditionally, a pragmatic approach has been adapted to the level of characterization for 
cell therapy preparations, as to date, most uses of cell therapy have been in urgent 
treatment of life-threatening conditions  such as leukemia. However, given the broad range 
of applications of cell therapy now under development, the  risk/benefit balance may  be  
very different and  a greater ability to predict clinical response may be required or 
mandated by  regulators. 
 
The type and level  of  characterization  necessary to demonstrate sustained viability and  
functionality of the final cell therapy products will depend on the cell type/s involved but 
should primarily address the demands of their application. The group concluded that in 
general, for final cell preparations for therapy, it will be important to consider not only 
markers of features that are expected for therapeutic function, but also markers that are 
contraindications for clinical use of the cells. The group considered that this area of 
discussion needed to be explored further through a workshop on cell viability and function  
(see Box 1 for Recommendation  1). 
 
In the case of pluripotent stem cells the group concluded that current cellular markers may 
not be sufficient in the absence of functional assays. How- ever, as part of the profile of 
expression, the cellular markers are important identity markers of the culture type. 
Nevertheless, functional assays (e.g., teratoma formation in immuno-compromised mice, 
embryoid body formation in vitro and directed differentiation) are needed to  complement  
currently  used  markers of self-renewal (e.g.,  Nanog,  Sox2,  Oct-4)  which  are necessary 
but not sufficient to demonstrate the pluripotent potential of these cells. 
 
Appropriate analytical methods for capturing the properties of cell preparations are often 
performed at key quality control points in bioprocessing. However, the group identified that 
these represent snapshots of a dynamic and often evolving cellular system. Mapping this 
process with in-process testing may well be crucial to successful preservation and recovery 
of a functional cell therapy product. Examples of clinical and scientific evaluation of primary 
tissues and cells have been developed in fields such as in vitro fertilisation (IVF) where 
cells must be used within a few hours. 
 
The group agreed that reference cell preparations may be useful but, in general, for cell 
therapies where the products are extremely diverse, these may need    to be product 
specific. Nevertheless, the group also concluded that it may be helpful to  develop  refer- 
ence materials for the analytical methods used to characterize cell preparations. 
 
 It was recognized that in the development of biotechnology, systems biology studies of the 
genome and transcriptome had been an important  factor  in the development of cell culture 
systems to assess the impact of different culture conditions [9], but relatively few studies 
had been performed on the impact of preservation [10,11]. The group agreed that further 
discussion on the application of such deep systems analysis for cell preparations for cell 
therapy could assist in the assessment of preservation methods. Furthermore, in- depth 
studies of different combinations of different culture media and matrices using high-
throughput approaches are likely to identify improved preservation and stability of models 
systems as had been developed for gametes [12,13] (see Box 2 for Recommendation  2). 
 
The potentially valuable contribution of low  oxygen culture conditions for cells in culture 
was recognized and recent publications that have demonstrated this for clinically relevant 
cells – for example in [14–17]. However, specific benefits for preservation and stability of 
cell preparations had yet to be demonstrated and required further research (see Box 1 for 
Recommendation 1). In conclusion, future studies of stability for cell therapy systems 
would need to con- sider culture medium, atmosphere and surface matrix in the context of 
their impact on cell  biology. 
 
The group concluded that experience with a broader range of assays that measured or 
correlated with cell function, should be developed for the evalu- ation of preservation 
techniques (see Table 1 & Box 1 for Recommendation 1) and that studies of model 
systems (Figure 1) were required. 
 
Session 4: The notion of viability 
 
It was agreed that there was very little in the  literature on thawing of cryopreserved 
material and there had been modest  progress  on  methodologies for  reliable  and  
reproducible  thawing.   However, the  method  of  thawing can be  critical to  successful 
recovery. Various thawing temperatures had been used between 32 and 40°C and it was 
agreed that  two key factors in determining the veracity of such data were full and accurate 
description of the thawing method and records of the actual temperature profile within 
individual vials. The group noted that there was now equipment available on the  market 
(e.g., ThawSTAR® CFT2 [Medcision, CA, USA] and VIAThaw [Asymptote/GE Healthcare, 
Cambridge, UK]) which could potentially improve reliability and reproducibility of thawing 
and recommended that  this was an area where rapid improvements could be made (see 
Box 3 for Recommendation 3) and some progress had already been made in the 
application of microwave-induced  thawing [18]. 
 
Understanding of delayed onset cell death in cell preparations post cryopreservation could 
give valuable information to help improve efficiency and efficacy of cell therapies [19,20]. 
Furthermore, the levels of nonviable cells and cell debris may be important in assessing 
whether a product is fit for use as these may cause the 
 product to cause inflammation or other undesirable responses. Cell death itself is also a 
complex process that may involve one or multiple different programmed and/or 
nonprogrammed biochemical processes some of which may be initiated as cell survival 
processes, such as autophagocytosis. The group agreed that there may be biological 
consequences of evading cell death, such as genetic change and cell transformation, 
which could impact on cell function and product safety. Thus, it was clear that  viability 
assessments  should  go beyond simple enumeration of cell numbers to facilitate a greater 
understanding of the cell system in question and there was a need for awareness that the 
same cell preparation can yield different results with different test methods [21–23]. The 
group  concluded that test methods for viability should provide data on both viable and 
nonviable populations, using a test regime based on a fundamental understanding of the 
cell preparations in question. In addition, there was a need for more sophisticated 
approaches to assess cell numbers. The group concluded that a future activity stimulated 
by the workshop steering group should be to address the needs for evaluation of the quality 
of in-put or ‘feedstock’ cells which should incorporate mechanisms of activation of cell 
death and identification of appropriate surrogate assays of functionality (see Box 4 for 
Recommendation  4). 
 
While it was broadly recognized that cellular stress is a significant issue to address in 
successful preservation, this is a  complex  aspect of  cell biology  due to the heterogeneity 
associated with the levels of syn- chronicity, phenotypes of cell populations and the 
physical heterogeneity of the culture systems. This heterogeneity could include shear 
force, oxygen, car- bon dioxide etc. Furthermore, it was acknowledged that priming a cell 
system (e.g., induction of enzymes protective against reactive oxygen species,  induction 
of heat shock protein expression) may influence successful survival after preservation, but 
relatively little is published in this area and current publications typically deal with 
preservation of gametes with specialized biological characteristics [24–28] (see Box 2 for 
Recommendation  2). 
 
Session 5: Formulation of & delivery of cell therapy products 
In order to facilitate a fundamental re-evaluation of approaches to preservation and stability 
of cell therapy products it will be important to understand the different formulations in which 
cells will be delivered to the patient and the cold-chain supply. The transfer of frozen or 
growth-inhibited cells from central storage to local storage, followed by recovery, 
formulation and injection to the patient must be considered as a whole process at an early 
stage in development of the product to generate an effective and efficient delivery chain to 
enable critical road-blocks to be managed proactively. 
 
Session 6: New technical opportunities 
Preservation technologies 
Significant effort has been put into freeze-drying cells, however, to date, success has been 
very limited [29,30]. The group concluded that this is clearly an area where further research 
could have a huge impact in the field of regenerative medicine and beyond. Another impor- 
tant area for development was the identification of new cryoprotective agents. Work was 
already being carried out with compounds used in nature such  as treha- lose, which 
combined with new cell permeabilization approaches (e.g., bacterial toxins, artificial 
membrane pores, micelles) [31] could provide new game-changing preservation 
 methodologies (see Box 1 for Recommendation 1). Plant and algal cell preservation 
experience (e.g., Scottish Association for Marine Sciences) and expertise in chemical 
excipients which modify in vivo structures may also be valuable and are being developed 
commercially by Croda (East Yorkshire, UK) [32]. 
 
Technologies for analysis of cryopreservation systems at ultra-low temperatures, require 
expertise in physics and materials sciences and include differential scanning calorimetry 
and neutron scattering and such technologies may have application in the design and 
evaluation of new methodologies for model systems (Figure 1). The group felt that this and 
other areas discussed at the workshop would benefit significantly from coordination of 
existing horizon-scanning activities to spread knowledge of new potential methodologies. 
Further, this should be linked to a ‘test bed’ function to provide rapid evaluation and 
development of generic benefits through qualification of new assays and development of 
control materials (see Box 4 for Recommendation 4). An example would be high-throughput 
evaluation of a range of cryoprotectants or protocols (see [13] and below) which could be 
facilitated by combinatorial experimental tools. 
 
 
Such tools might include the bead technology developed by Plasticell Ltd (Stevenage, UK) 
for the study of stem cell differentiation, which apparently can be used with alginate 
encapsulated cells (personal communication Dr Y Chen, Plasticell Ltd [33]). 
 
Cryoprotectants 
Various cryoprotectant products are on the  market but delegates agreed that these were 
largely based on well-proven methods and reagents. The workshop members felt that there 
could be real benefits for cell therapies through exploring new approaches and use of novel 
excipients (e.g., Croda) may also be helpful. Generation of  new  cryoprotective  agents  
molecules is also an area of active research for some applications [34,35]. Large libraries of 
such molecules can be synthesized, however, the rate limiting step is testing them with 
cells under conditions representative of standard cryopreservation. 
 
Delegates concurred that there was a general perception in the field that dimethylsulphoxide 
(DMSO), the cryoprotectant most commonly used in preservation of cells for clinical use, 
was undesirable given the broad- ranging and potentially toxic impact on cell biology. It had 
been proposed that in the long term DMSO should be replaced. The group felt that whilst 
DMSO could be deleterious under certain circumstances [36], this perception was, to date, 
causing some companies to consider suboptimal systems for cryoprotection. It was agreed 
that a published review of the reality of DMSO toxicity would be extremely valuable (see 
Box 5 for Recommendation 5). This should include the long his- tory of safe use (notably in 
bone marrow transfusion for more than 40 years), documented adverse events, 
effectiveness of enhanced removal methods, future need for new alternatives and a way 
forward to identify and select these. However, the group also agreed on the need to explore 
alternatives to DMSO through the engagement of chemists, to select and screen appropriate 
compounds (see Box 1 for Recommendation 1). 
 
Ice-nucleation 
The group unanimously agreed that ice nucleation was a critical but largely uncontrollable 
variable in small sample volumes. This could result in variation in cryopreservation which 
 may be observed between individual cryovials filled from the same batch of cell suspen- 
sion (personal communication, Dr J Morris, Asymptote Ltd./GE Healthcare, Cambridge, UK). 
 
Chemical inducers of nucleation had  been developed for addition to preservation medium 
and some had achieved regulatory acceptance for clinical use. Other technologies 
included bubbling of nitrogen vapor through the medium which required clinical grade 
liquid nitrogen. Procedures to assess and control the quality of liquid nitrogen  under  GMP 
where some manufacturers consider it a product excipient were required. However, a 
formal standard for clinical grade liquid nitrogen has yet to be established, although 
requirements for storage system cryogens are covered in regulatory guidance such as ICH 
Q8 [37]. Ultra-sonic treatments to induce ice nucleation have also been trialed, but these 
depend upon inducing cavitation which can cause serious local heating and shock  events 
[38]. 
 
Cooling rates 
The use of linear cooling rates is widespread in current technology but it was agreed that 
few systems achieve truly linear cooling and nonlinear rates or multiramp profiles [39] are 
known to provide significant improve- ments in cell preservation [40]. Investigation of 
nonlinear rates could provide some ‘quick wins’ in the development of new preservation 
methods. The group proposed that nonlinear cooling rates should be an area for further 
discussion and coordination. (see Box 4 for Recommendation 4). Furthermore, in order to 
avoid misinterpretation of cooling rate data, it is important to be sure that the actual cooling 
rate experienced by the cell preparation is measured during cooling experiments and not just 
the surrounding environment. New ultrasound-based technologies are currently being used 
as novel biosensors in cell culture systems (such as those developed by OJ-bio Ltd [41]). 
These systems could also be considered to monitor cooling rate but may not offer bio-survival 
data as the technique is dependent on antibody interaction. 
 
Cell & tissue encapsulation 
Encapsulation has been used in the preservation of   a variety of organisms and tissues 
including bacteria, fungi, plant meristems and  disaggregated  liver and pancreatic cells 
[42–45]. The group felt that the potential of this technology, in assisting the stabilization of 
mammalian cell membranes and avoidance of ice damage, could offer significant 
advancements in cryopreservation and storage stability. Use of either barium or calcium 
ion-induced polymerization of alginate was now  used  widely  with mammalian cells which 
could also be recovered with good viability from alginate capsules following controlled 
depolymerization. Published examples include fibroblasts [46], disaggregated liver [45], 
pancreatic islets [47,48] and differentiated pluripotent stem cells [49]. Further- more, novel 
developments for this approach include syringe preservation. 
 
Session 6: Storage systems 
There was unanimous agreement by delegates that much of the equipment for cooling and 
storage at ultralow temperatures had not progressed significantly for decades. It was noted 
that further discussion with manufacturers could yield some progress toward 
modernization and improvement of their suitability for use with the new generation of cell 
therapeutics (see Box 4 for Recommendation 4). In contrast, data storage and inventory 
control were areas where real advances had been made. In particular, it was now possible 
using radiofrequency identification (RFID) technology (such as being developed by 
 CryoGatt Ltd, Hertfordshire, UK [50]) to check inventories of stored material. In addition, 
the technology had been developed by groups such as IBMT (Fraunhofer Institute, 
Sulzbach, Germany [51]) which provided an ultra-cold resistant chip within individual 
cryovials which store the temperature history and detailed cell banking data for each vial. 
The group concluded that there were now automated access systems (e.g., see [51]) which 
may provide cost-effective storage and noninvasive temperature monitoring solutions for 
cell therapies. 
 
Session 7: Thawing methods 
As already detailed, new  improved  methodologies  for thawing are required and new 
approaches such as ultrasound induced melting and rapid thawing using electromagnetic 
excitation of nanoparticles may provide suitable solutions for certain applications and are 
available commercially (e.g., Nano Biosils [52],  oi-li- tech nanomaterials [53]). Clearly, the 
mechanism of heating should be carefully investigated for adverse effects on the cells and 
compounds to which therapeutic cells are exposed to achieve clinical and regulatory 
acceptability and approval. However, given that modern vial materials usually restrict heat 
transfer rates, new methods for rapid and reproducible thawing are urgently needed that 
provide efficient and  rapid thawing to assure adequate cell  survival. 
 
Session 8: Storage & shipment of cells 
Cryoshipments 
Shipment of cryopreserved material will continue to add  significant cost to  the  delivery of  
cell therapies based on current methods. Key issues for  shipment of cryopreserved cells 
which would benefit from new developments include: 
• The requirement for stable ultra-low temperatures to be maintained for days or weeks, 
under, at  times,  hostile  environmental  conditions,  without interventions such as 
recharging cryogens by shipping agents. 
• Sealing and containment systems that prevent exposure to environmental contamination. 
• Robust labeling conventions, standardized product nomenclatures (such as the new WHO 
INN standard nomenclature for cell therapy products [54]) and labeling materials resistant 
to ultra-low temperatures and of suitable size to fit on cryovials. 
 
It was noted that there were a number of existing coordinating activities that could provide 
useful sup- port and in particular the Knowledge Transfer Net- work manufacturing activity 
on transplantation should be contacted [55] (see Box 4 for Recommendation  4). 
 
Transport of live cultures 
The clinical application  of  cell-based  therapeutics  has come to the fore, with the number 
of novel clinical trials demonstrating a dramatic increase in the last decade, accompanied 
by an emergence of approved cell therapy products to the market. A major bottleneck for cell 
therapeutics is that the products comprise live cells with short shelf lives. This is a 
significant challenge for successful completion of quality, safety and efficacy testing, and 
subsequent distribution from the donor   or bank, to sites of processing and back to the 
clinic. Although cryopreservation is currently to be required for the long-term storage of 
cells, some cellular systems are not amendable to the application of current methods 
(discussed above). Thus, the transport of cells in their liquid viable state may be necessary 
 or indeed advantageous [56]. In a recent assessment by experts in the field, it was 
considered critical that improved preservation and transport-enabling technologies be 
developed in order to eliminate GMP-regulated process steps of preservation removal and 
cell thawing [57]. This might fit with centralized production facilities for cell therapies, with 
cryobanking for stock control, followed by thawing and distribution of live cell products. 
 
Hypothermic storage of cells (over a range of 0–34°C), has been recorded to avoid many of  
the issues associated with cryopreservation. However, delegates still shared concerns over 
limited time-windows where difficulty in timing the transfer of cells   to  the  clinic  due  to  a  
restricted,  inflexible shelf-life could result in a high level of wastage of materials [58]. 
Extending the shelf-life of hypothermically stored cellular products, without significant loss 
of viability and therapeutic potency, could therefore, offer a number  of benefits at multiple 
stages during bioprocessing for both autologous and allogeneic therapies. Extended shelf 
life would extend the period for completion of quality assurance, sterility testing,  
characterization  and efficacy testing. It would also reduce the risk of wastage due to 
inadequate  continuity  between  sites of processing and disrupted  patient  scheduling  at  
the clinic. Additionally, where a course of therapy requires application of repeat tissue 
samples or cell dosing, multiple products could be stored at the clinic obviating the 
requirement for multiple  shipments. 
 
Current work at the University of Newcastle had developed alginate encapsulation of cells 
for the hypo- thermic storage of a range of cell types [59]. For some products a combination 
of cryo-storage and hypothermic storage to obtain the benefits of long-term cryostorage 
with the ease of handling and reduced ship- ping costs of hypothermic storage of the 
thawed cells could be advantageous. The group concluded that this approach should be 
considered as an area with significant potential benefit that would be enhanced by 
collaboration between academics and manufacturers (see Box 1 for Recommendation 1). 
Ongoing work at the University of Newcastle was exploring the bio- logical mechanism 
behind the alginate encapsulation hypothermic storage approach using adipose derived 
stem cells (stromal fraction) and image analysis at IBMT (see above) has provided useful 
direct cryomicroscopy evaluation of the cryopreservation process in individual  alginate 
beads. 
 
Live cultures can be shipped with success and the use of so-called ‘hibernation media’ 
have been used for many years for therapeutic cells. It was noted that HypoThermasol 
FRS (BioLife Solutions, WA, USA) with a published composition including DMSO, has been 
qualified for shipment at 2–8°C and is capable  of sustaining viability of cell preparations 
for up to 30days. However, its application in other cells-types had not yet been investigated 
and the group felt this could be a valuable and straightforward piece  of  work that could be 
coordinated between interested researchers and the manufacturer (see Box 3 for 
Recommendation 3). Shipment at higher temperatures had also been qualified by 
Organogenesis Inc.  [60] who had successfully sustained cell viability following transport at 
25°C for 5 days and 20°C for 15 days. Other approaches to metabolic regulation  control  
may facilitate liquid ambient (around 20°C) temperature which does not appear to 
necessarily impact on  cell viability  and  function  [61–63].  The  group felt this deserved 
further expert discussion to identify the key metabolic changes from 37°C down to 20°C 
(see Box 4 for Recommendation 4). The group also agreed that perfluorocarbons for 
oxygen support [64] and hydrogels also presented potentially valuable reagents to explore 
 for cell shipment. 
 
In common  with  the  all-too-many  publications of ‘successful’ cryopreservation methods, 
publications on hypothermic storage methods (see above) also lacked standardization in 
terms of validation of success. The value of such publications to industry and healthcare, 
as well as in taking the science for- ward, was currently limited. The group  concluded that 
this  situation  could  be  significantly  improved if a set of ‘standards’ could be agreed that 
included some quantifiable assessment of functionality relevant to the therapeutic purpose 
of  the  product.  One such model of potential value has been developed, which 
establishes a single value combining percentage viable cell release (not simply percentage 
cell viability) with mitochondrial metabolic activity post-cryopreservation and release [65]. 
 
Long-term storage issues 
A range of events were known to cause loss of viability in preserved materials including 
environmental radiation, poor handling practice (resulting in partial thawing of material), 
temperature cycling above the glass transition temperature (leading to crystal growth and 
cell death) and physical shock of vitrified systems causing loss of viability. It is important to 
understand the factors that determine the critical storage temperature. Studies had shown 
that human cells can be stored for more than 30 years and that other biological cellular 
materials for more than 50 years (for a review see [66]). Stability of viability in 
cryopreserved liquid cell suspensions was known to be very limited at temperatures around 
-80°C and was totally unsuitable for vitrified material, where the glass transition 
temperature was much lower, in other words, often below -150°C. The manufacturing 
requirements for storage of cryopreserved materials may vary depending on whether the 
material is stored short term (e.g., awaiting quality con- trol, shipment) or if the material is in 
long-term storage such as a manufacturer’s master cell bank which may be used over 
several decades. Approaches, to simulate long- term storage using ‘accelerated aging’ 
techniques, have been developed for seeds and protein preparations [67,68] but new 
approaches may be needed for preserved cells, possibly focusing changes of phase and 
micro-environment. It was proposed that such approaches should be considered for 
adaptation for cell therapies. It is clear that long-term storage vessels need to be 
redesigned to assure low maintenance, well-documented, secure  and contamination free 
systems – this could be the subject of a further workshop sessions with manufacturers, cell 
biologists, microbiologists, cryobiologists and clinicians (see Box 4 for Recommendation 4). 
 
Conclusion 
It was strongly argued that the broadly held perception that the challenges of 
cryopreservation were resolved and did not need further development was mistaken and had 
been a significant reason for the lack of progress in this area. Current press and public 
interest, in light of recent court rulings on cryonics, only emphasize the need for measured 
scientific and technological approaches. These along with the application of more relevant 
characterization of cell biological functions, could lead to significant improvements in yield of 
viable and functional cells and greater efficiency in cell therapy production chains. It was 
concluded that these benefits would justify the R&D investments recommended by the group 
and furthermore, could reduce the cost of future regenerative medicine products. The 
recommendations agreed by the workshop delegates are summarized below. 
 
Future perspective 
 Once new cell therapies show efficacy there will be an immediate demand for efficient 
international delivery of cell therapies which will be dependent upon the ability to store and 
ship cell therapy products stably and reliably. New developments to support this will come 
from translation of learning from one cell product to another and in considering new solutions 
to storage and recovery equipment. Investigation and evaluation of new cryoprotectants in 
different cell systems will also be important in the coming years and research funders should 
be encouraged to support new coordinated research programs to facilitate early evaluation 
and translation in industry. 
 
Financial & competing interests disclosure  
The authors have no relevant affiliations or financial involvement with any organization or 
entity with a financial interest in or financial conflict with the subject matter or materials 
discussed in the manuscript other than where the company name is given in their affiliation. 
This includes employment, consultancies, honoraria, stock ownership or options, expert 
testimony, grants or patents received or pending, or royalties. 
No writing assistance was utilized in the production of this manuscript. 
 
 
Executive summary 
 This report summarizes consensus among a specially selected expert group on key 
issues in assuring stable storage and shipment of cell therapy products. 
 The discussion covered a broad range of fundamental cell biology and preservation 
issues which need to be addressed to establish and qualify preservation and storage 
methods suitable for cell-based medicines. 
 In particular, the group discussed potential model cellular systems for preservation 
development and certain neglected but vital aspects of fundamental cell biology and 
cryopreservation. 
 They also addressed the need for effective characterization and viability assessment 
of preserved cells and approaches to formulation of preserved cell-based medicines. 
 Finally, the group also considered new technical opportunities for cryopreservation, 
storage, shipment and cell thawing. 
Workshop  recommendations 
 A number of areas were considered in need of fundamental scientific development 
and are summarized in Recommendations 1 and 2. Other recommendations 
addressed potential early benefits that could be obtained from dissemination of 
current techniques and new instruments (Recommendation 3) and opportunities for 
advanced understanding of the issues through key coordination activities 
(Recommendation 4 and 5). 
Conclusion 
 The group concluded that there were clear and significant benefits to be gained from 
implementation of these recommendations for effective safe and efficient roll-out of 
cell therapies. 
 The issues of cell stability and preservation need to be addressed early in product 
development and are of particular importance to underpin the current dramatic 
 expansion of cell-based medicines such as 
immunotherapies including chimeric antibody T cells. 
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Figures and Tables: 
 
Box 1. Recommendation 1. 
A coordinated program of research into cryopreservation methods using relevant 
exemplars from cell therapy. This would include: 
 Development of a set of simple model systems that could be used to understand the 
challenges of preserving key types of cell therapies 
 A large study investigating different media and matrices for preservation of model 
systems engaging expertise in – omics analysis 
 Further R&D funding for investigation of cell freeze-drying and cell permeabilization 
methods that could provide  game-changing discoveries 
 Investigation of alternative cryoprotectants to dimethylsulphoxide which engages 
chemistry expertise to select and screen appropriate compounds 
 Investigation of a combinatorial approach combining cryopreservation with 
hypothermic storage 
 
  
Figure 1. Potential models systems to assess new preservation strategies. 
Donor cell harvest to recipient time: 
b) Hours: risk assessment similar to transplantation and bioprocessing should assure 
little or no change in the cell preparation. 
c) Days: key additional hazard is expansion of microbial, contamination requiring new 
rapid methods and loss of viability and efficacy requiring careful characterization. 
d) Preservation steps for seed stock enable long-term storage of seed stocks, 
intermediate cell preparations and final product thus permitting careful characterization 
and safety testing to provide greater confidence in efficacy and safety. 
 
 
Box 2. Recommendation 2. 
A coordinated research program into the fundamental elements of cell biology 
associated with stability and successful preservation. This should include: 
 The development and application of more appropriate and quantified measurement 
of viability and survival specified for particular applications, including epigenetic, 
metabolomics and transcriptomic profiling 
 Careful comparative studies to elucidate the benefits of well controlled hypoxic 
culture conditions for 
therapies 
 
Table 1. Levels of analysis for evaluation of viability and function for cell therapies. 
Feature of cell biology Methods and exemplar studies 
 
Processing involving combinations of: 
 
• Cell culture with or without 
expansion 
• Purification 
• Cell development chemical or 
physically induced changes 
– for example differentiation 
• Genetic modification 
Single defined 
therapeutic cell type  
Tissue or cell 
preparation Complex mixture 
of cells 
Combination of 
cells and matrix 
 
Cryopreservation 
of tissue or 
primary cells 
Cryopreservation of: 
• Processed tissue 
• Processed primary cells 
• Cell lines or recombinant cells 
 
Cryopreservation 
of tissue or 
primary cells 
 Membrane integrity/function (and 
lipidomics) 
Membrane associated enzymes 
(fluorescein diacetate test for membrane 
esterases), membrane degradation test 
such as malondialdehyde assay, 
lipidomics 
Structure and function of subcellular 
organelles 
Mitochondria, nucleus, endoplasmic 
reticulum, protein folding 
Biochemical pathways and key molecular 
complexes 
Proteasome, epigenome, transcriptome 
and metabolome 
Metabolic flux Mitochondrial functions 
Adherence mechanisms Integrin expression 
Single  cell analysis Studies of subpopulation analysis using live 
cell imaging, Matrix-assisted laser 
desorption/ 
ionization  (MALDI),  Raman  spectroscopy,  
single cell analysis (e.g., sequencing, 
expression profiling) 
electrophysiology, cryomicroscopy among 
others. 
Image analysis and morpholomics New approaches to applying metrics to 
cell morphology such as neurite  
outgrowth 
Cell functionality and response Real-time measurement of calcium 
imaging Response to reference 
compounds including TNF- and toxicants 
Rate of cell death Assessment of rates of replication and 
death 
  
 
 
 
Box 3. Recommendation 3. 
The group identified areas where translation of current knowledge and expertise 
could lead to early improvements in current preservation and shipment technology 
and these included: 
 Investigation of ‘hibernation media’ which had proved successful with some cell 
types and their assessment for broader application with cell therapy preparations 
 Use of newly available thawing equipment to improve reliability of thawing and viable 
cell yield 
 
Box 4. Recommendation 4. 
 The group proposed that further interaction between academic, commercial and 
regulatory stakeholders should be promoted in meetings and workshops specifically 
in the following areas: 
 Coordination of current horizon-scanning activities to spread knowledge of new 
potential methodologies.   This should be linked to a ‘test bed’ function to provide 
rapid evaluation and development of generic benefits through qualification of new 
assays and control materials 
 Assessment of the requirements for long-term storage systems to assure low-
maintenance, well-documented, secure and contamination-free systems and the 
development of accelerated ageing studies which could be useful for cell therapies 
Workshop activity should include manufacturers, cell biologists, microbiologists, 
cryobiologists and clinicians 
 Address the needs for evaluation of the quality of ‘feedstock’ cells or starting 
cultures, incorporating consideration of mechanisms of activation of cell death and 
identification of appropriate assays of viability and function 
 Evaluation of the value that nonlinear cooling rates might hold for improvement in 
preservation technology 
 The impact of ambient temperature storage on cell biology 
 Cross agency coordination should be promoted including the Knowledge Transfer 
Network (KTN) manufacturing activity on transplants 
Box 5. Recommendation 5. 
 The group identified that a published review addressing the reality of 
dimethylsulphoxide toxicity would be extremely valuable. This should include history 
of use, documented adverse events, effectiveness of enhanced removal methods, 
future need for new alternatives and a way forward to identify and select these 
 
